Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Céline, Chu"'
Autor:
Céline Chu, Sophie Barbou des Courières, Kevin Fournier, Sophie Kelley, Jacques-Olivier Bay, Marie Gadeyne
Publikováno v:
Bulletin du Cancer
Bulletin du Cancer, John Libbey Eurotext, 2022, 109 (1), pp.20-22. ⟨10.1016/j.bulcan.2021.11.008⟩
Bulletin du Cancer, John Libbey Eurotext, 2022, 109 (1), pp.20-22. ⟨10.1016/j.bulcan.2021.11.008⟩
International audience
Autor:
Céline, Chu, Sophie, Barbou des Courières, Kevin, Fournier, Sophie, Kelley, Jacques-Olivier, Bay, Marie, Gadeyne
Publikováno v:
Bulletin du cancer. 109(1)
Autor:
Marie-Sophie Noël-Hudson, Ludovic Bigot, Mélanie Polrot, Diane Goéré, Valérie Boige, Laurence Bonhomme-Faivre, Céline Chu, Robert Farinotti, Patrick Gonin, Sylvie Marion
Publikováno v:
Fundamental & Clinical Pharmacology. 27:434-442
KRAS mutation is a negative predictive prognostic factor during metastatic colorectal cancer treatment with antiepidermal growth factor receptor antibodies. For affected patients, new therapeutics must be explored. Our objective was to study efficacy
Autor:
Céline Chu, Patrick Gonin, Robert Farinotti, Laurence Bonhomme-Faivre, Mahamadou Tandia, Chadi Abbara, Mélanie Polrot
Publikováno v:
Fundamental and Clinical Pharmacology
Fundamental and Clinical Pharmacology, 2014, 28, pp.652-60. ⟨10.1111/fcp.12071⟩
Fundamental and Clinical Pharmacology, 2014, 28, pp.652-60. ⟨10.1111/fcp.12071⟩
International audience; In a previous study, we showed that cetuximab, a monoclonal antibody directed towards epidermal growth factor receptor, could inhibit P-glycoprotein (P-gp), an efflux protein of ATP-binding cassette family, and lead to an incr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::852cd2c80c7f145b932c1ce67dcfbde4
https://hal.univ-angers.fr/hal-03333949
https://hal.univ-angers.fr/hal-03333949
Autor:
Jean-meidi Alili, Chadi Abbara, Laurence Bonhomme-Faivre, Marie-Sophie Noel-Hudson, Robert Farinotti, Céline Chu
Publikováno v:
Annals of Oncology. 23:iv81
Introduction Bevacizumab (BVZ; Avastin®) is an anti-VEGF antibody associated with irinotecan for the treatment of metastatic colorectal cancer. P-glycoprotein (P-gp) has a major role in the multidrug resistance (MDR) phenomenon, responsible for the